For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS)
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) Lesions (NCT07275723) | Shanghai Shengdi Pharmaceutical Co., Ltd | 2025-11-14 |
Track For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS) automatically
Every clearance here is in the API, with alerts when new ones post.